Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants

Nicola Flaum; Emma J Crosbie; Emma R Woodward; Fiona Lalloo; D Gareth Evans

doi:10.1016/j.ejca.2019.10.018

Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants

Eur J Cancer. 2020 Jan:124:88-90. doi: 10.1016/j.ejca.2019.10.018. Epub 2019 Nov 21.

Authors

Nicola Flaum¹, Emma J Crosbie², Emma R Woodward³, Fiona Lalloo⁴, D Gareth Evans⁵

Affiliations

¹ Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK; Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK. Electronic address: Nicola.flaum@manchester.ac.uk.
² Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK; St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, M13 9WL, UK. Electronic address: Emma.crosbie@manchester.ac.uk.
³ Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK; Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK. Electronic address: Emma.woodward@mft.nhs.uk.
⁴ Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK; Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK. Electronic address: Fiona.lalloo@mft.nhs.uk.
⁵ Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK; Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK; Prevention Breast Cancer Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Manchester, M23 9LT, UK; The Christie NHS Foundation Trust, Manchester, M20 4BX, UK; Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, M20 4BX, UK. Electronic address: Gareth.evans@mft.nhs.uk.

PMID: 31760313
DOI: 10.1016/j.ejca.2019.10.018

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
BRCA1 Protein / genetics*
BRCA2 Protein / genetics*
Female
Humans
Middle Aged
Ovarian Neoplasms / genetics*
Ovarian Neoplasms / pathology

Substances

BRCA1 Protein
BRCA1 protein, human
BRCA2 Protein
BRCA2 protein, human

Grants and funding

CRUK_/Cancer Research UK/United Kingdom